Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab IV switch in rheumatoid arthritis
NCT01962974Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of golimumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 20 Response at 24 weeks. Started Oct 2013; status: terminated.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01962974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962974.